CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Drug discovery startup Pepper Bio hopes to challenge Eroom’s law with new funding

From TechCrunch

By Anna Heim

November 30, 2023

Drug discovery startup Pepper Bio hopes to challenge Eroom’s law with new funding

The biotech startup's $6.5 million seed round is led by VC firm NFX but it is perhaps equally noteworthy to see that Merck is also participating in the round.

© 2023 TechCrunch. All rights reserved. For personal use only.

Most Recent

NextDC's stock fell as much as 44% to A$5.15 after the Australian data center company cut its earnings forecast by over a third; shares were above A$16 in June

NextDC plunge adds to sector woes as Nvidia holds talks over injecting capital into Firmus after failed IPO

Oct 20, 2026

Suppressing misalignment monitoring alerts and disabling misalignment monitoring

Research on aligning AI with human values and intent, and reports documenting model failures.

Oct 20, 2026

Fidelity launches global innovators equity fund in Hong Kong and Singapore

The new Luxembourg-domiciled SICAV fund will invest in companies positioned to drive or benefit from structural change and long-term trends.

Oct 20, 2026

Australian data center operator NextDC's shares plunge 40% after it slashes earnings forecast

The company cited power supply delays at its Melbourne facility amid local community and stakeholder opposition for lowering earnings forecast.

Oct 20, 2026

Similar Posts

Houston fintech startup raises $8M seed round led by local VC

Brassica Technologies Inc. closed its seed round at $8 million with Houston-based Mercury Fund leading the round. Valor Equity Partners, Long Journey Ventures, NGC Fund, Neowiz, Broadhaven Ventures, Armyn Capital, VC3DAO, Alpha Asset Management (Korea), and other global FinTech investors participated in the round as well.

Apr 10, 2023

Radical Numerics Raises $50 Million Seed Round To Build General Biological Intelligence

Radical Numerics raised a $50 million seed round to scale next-generation AI models for biology, including pathogen detection and biological design. The round was led by Emergence Capital with participation from Obvious Ventures, Triatomic Capital, Factory, and First Spark Ventures.

Jun 15, 2026

Potato, an Autonomous Science Agent, Closes $4.5M Seed Round Led by Draper Associates

Potato closed a $4.5 million seed round led by Draper Associates with Dolby Family Ventures, Boost VC, Ensemble VC, and Silicon Badia to develop autonomous AI scientists for biotech research.

Apr 7, 2025

Sequoia unveils $950M in new early-stage funds as it strives to be ‘only as good as our next investment’

The legendary firm launched a $750 million early-stage fund targeting Series A startups and a $200 million seed fund.

Oct 27, 2025